GOLDMAN SACHS GROUP INC - VERVE THERAPEUTICS INC ownership

VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 137 filers reported holding VERVE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.3%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of VERVE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,725,421
-45.6%
205,537
-23.0%
0.00%0.0%
Q2 2023$5,007,713
+32.1%
267,078
+1.6%
0.00%0.0%
Q1 2023$3,791,638
-50.3%
262,943
-33.3%
0.00%
-50.0%
Q4 2022$7,628,428
-26.8%
394,234
+30.0%
0.00%0.0%
Q3 2022$10,421,000
+811.7%
303,353
+305.8%
0.00%
Q2 2022$1,143,000
-52.9%
74,759
-29.7%
0.00%
-100.0%
Q1 2022$2,427,000
+25.6%
106,368
+103.0%
0.00%
Q4 2021$1,932,000
-2.5%
52,400
+24.3%
0.00%
Q3 2021$1,981,000
-72.3%
42,154
-64.4%
0.00%
-100.0%
Q2 2021$7,140,000118,5130.00%
Other shareholders
VERVE THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Alphabet Inc. 10,974,011$167,683,0009.10%
ARCH Venture Management, LLC 2,508,809$38,335,0004.67%
Casdin Capital, LLC 3,138,167$47,951,0004.05%
M28 Capital Management LP 178,500$2,727,0003.06%
Redmile Group, LLC 1,833,547$28,017,0001.07%
Cormorant Asset Management, LP 700,710$10,707,0000.81%
Novo Holdings A/S 927,100$14,166,0000.70%
Pinz Capital Management, LP 51,800$792,0000.54%
PFM Health Sciences, LP 845,186$12,914,0000.49%
Artal Group S.A. 400,000$6,112,0000.33%
View complete list of VERVE THERAPEUTICS INC shareholders